Skip Navigation

European Heart Journal 2001 22(18):1741-1747; doi:10.1053/euhj.2000.2531
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Li-Saw-Hee, F.L
Right arrow Articles by Lip, G.Y.H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li-Saw-Hee, F.L
Right arrow Articles by Lip, G.Y.H
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function

F.L Li-Saw-Hee, A.D Blann, D Gurney and G.Y.H Lipf1

Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, U.K.

revised November 7, 2000; accepted November 8, 2000

Abstract

Background Atrial fibrillation is associated with increased risk of stroke and thromboembolism, possibly by conferring a prothrombotic or hypercoagulable state. However, it is unclear whether or not this differs in the clinical subgroups of chronic atrial fibrillation patients, that is, in those with paroxysmal, persistent or permanent atrial fibrillation. We therefore hypothesized that: (i) there are differences in the prothrombotic state between these patients; and (ii) reduction in indices of hypercoagulability would follow elective electrical cardioversion of persistent atrial fibrillation and the return of left atrial function.

Patients and Methods We studied 69 patients with chronic atrial fibrillation: 23 with paroxysmal atrial fibrillation (16 males; mean age 65 years±SD13); 23 with persistent atrial fibrillation (16 males; 65 years±13), with a mean duration of atrial fibrillation of 3 months (range 2 to 6 months); and 23 with permanent atrial fibrillation (16 males; 67 years±10). Blood results were compared to 20 age- and sex-matched healthy controls. The patients with persistent atrial fibrillation then underwent elective DC cardioversion, with Doppler echocardiographic examinations and bloods tests performed prior to cardioversion, and at 3 and 12 weeks afterwards. The prothrombotic state was quantified by measurement of plasma levels of fibrinogen, soluble P-selectin (an index of platelet activation) and von Willebrand factor (a marker of endothelial dysfunction).

Results Permanent atrial fibrillation was associated with significantly raised levels of von Willebrand factor, soluble P-selectin and fibrinogen (all P<0·001); paroxysmal atrial fibrillation with significantly elevated levels of plasma von Willebrand factor (P=0·0067) and fibrinogen (P=0·0001) but not soluble P-selectin (P=0·472); and persistent atrial fibrillation with normal levels of fibrinogen, von Willebrand factor and soluble P-selectin when compared to healthy controls (all P=ns). Stepwise multiple regression analyses demonstrated that the presence of atrial fibrillation was an independent predictor of abnormal von Willebrand factor, fibrinogen and soluble P-selectin levels. Electrical cardioversion of the patients with persistent atrial fibrillation did not significantly alter levels of von Willebrand factor (P=0·766), soluble P-selectin (P=0·726) or fibrinogen (P=0·50) despite maintenance of sinus rhythm and a significant return of left atrial systolic function (as quantified by the presence of A wave on Doppler echocardiography) at 3 months.

Conclusion There were significant differences in the prothrombotic state when patients with paroxysmal and permanent atrial fibrillation are compared to matched patients with persistent atrial fibrillation or controls in sinus rhythm. Cardioversion of persistent atrial fibrillation did not significantly alter indices of hypercoagulability even after 3 months maintenance of sinus rhythm, despite the return of atrial systole.

Key Words: Atrial fibrillation, electrical cardioversion, haemostatic markers, left atrial function

f1 Correspondence: Dr G. Y. H. Lip, Haemostasis Thrombolis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, U.K.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ChestHome page
A. Choudhury, I. Chung, N. Panja, J. Patel, and G. Y. H. Lip
Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation: Relationship to Soluble P-Selectin, Stroke Risk Factors, and Risk Factor Intervention
Chest, September 1, 2008; 134(3): 574 - 581.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. G. Akar, W. Jeske, and D. J. Wilber
Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction.
J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1790 - 1793.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R. Nieuwlaat, T. Dinh, S. B. Olsson, A. J. Camm, A. Capucci, R. G. Tieleman, G. Y.H. Lip, H. J.G.M. Crijns, and on behalf of the Euro Heart Survey Investigators
Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?
Eur. Heart J., April 1, 2008; 29(7): 915 - 922.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
H. Duygu, V. Barisik, H. Kurt, U. Turk, E. Ercan, and S. Kose
Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation
Europace, February 1, 2008; 10(2): 210 - 214.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
B. Freestone, A. Y. Chong, S. Nuttall, A. D. Blann, and G. Y. H. Lip
Soluble E-selectin, von Willebrand Factor, Soluble Thrombomodulin, and Total Body Nitrate/Nitrite Product as Indices of Endothelial Damage/Dysfunction in Paroxysmal, Persistent, and Permanent Atrial Fibrillation
Chest, October 1, 2007; 132(4): 1253 - 1258.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Choudhury, I. Chung, A. D. Blann, and G. Y.H. Lip
Platelet Surface CD62P and CD63, Mean Platelet Volume, and Soluble/Platelet P-Selectin as Indexes of Platelet Function in Atrial Fibrillation: A Comparison of "Healthy Control Subjects" and "Disease Control Subjects" in Sinus Rhythm
J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1957 - 1964.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. Choudhury, I. Chung, A. D. Blann, and G. Y. H. Lip
Elevated Platelet Microparticle Levels in Nonvalvular Atrial Fibrillation: Relationship to P-Selectin and Antithrombotic Therapy
Chest, March 1, 2007; 131(3): 809 - 815.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Rotter, P. Jais, M.-C. Vergnes, P. Nurden, Y. Takahashi, P. Sanders, T. Rostock, M. Hocini, F. Sacher, and M. Haissaguerre
Decline in C-Reactive Protein After Successful Ablation of Long-Lasting Persistent Atrial Fibrillation
J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1231 - 1233.
[Full Text] [PDF]


Home page
Eur Heart JHome page
C. J. Boos, R. A. Anderson, and G. Y.H. Lip
Is atrial fibrillation an inflammatory disorder?
Eur. Heart J., January 2, 2006; 27(2): 136 - 149.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
F Marin, V Roldan, V E Climent, A Ibanez, A Garcia, P Marco, F Sogorb, and G Y H Lip
Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation
Heart, October 1, 2004; 90(10): 1162 - 1166.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. S. G. Conway, P. Buggins, E. Hughes, and G. Y. H. Lip
Relationship of interleukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation
J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2075 - 2082.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. P. Mathew, M. L. Fontes, I. C. Tudor, J. Ramsay, P. Duke, C. D. Mazer, P. G. Barash, P. H. Hsu, and D. T. Mangano
A Multicenter Risk Index for Atrial Fibrillation After Cardiac Surgery
JAMA, April 14, 2004; 291(14): 1720 - 1729.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S Kamath, A D Blann, B S P Chin, and G Y H Lip
Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation
Heart, September 1, 2003; 89(9): 1093 - 1095.
[Full Text] [PDF]


Home page
StrokeHome page
N. A.Y. Chung, F. Belgore, F. L. Li-Saw-Hee, D. S.G. Conway, A. D. Blann, and G. Y.H. Lip
Is the Hypercoagulable State in Atrial Fibrillation Mediated by Vascular Endothelial Growth Factor?
Stroke, September 1, 2002; 33(9): 2187 - 2191.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. Kamath, A. D. Blann, G. J. Caine, D. Gurney, B. S.P. Chin, and G. Y.H. Lip
Platelet P-Selectin Levels in Relation to Plasma Soluble P-Selectin and {beta}-Thromboglobulin Levels in Atrial Fibrillation
Stroke, May 1, 2002; 33(5): 1237 - 1242.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
G.Y.H. Lip and F.L. L. S. Hee
Paroxysmal atrial fibrillation
QJM, December 1, 2001; 94(12): 665 - 678.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
N.M. Al-Saady and M. Sopher
Prothrombotic markers in atrial fibrillation: what is new?
Eur. Heart J., September 2, 2001; 22(18): 1635 - 1639.
[PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.